Steatohepatitis/Metabolic Liver Disease News

BIO89-100, a long-acting glycopegylated fibroblast growth factor 21 analogue, decreased spleen volume that correlated with reduced liver fat, liver fat volume and PRO-C3 levels among patients with nonalcoholic steatohepatitis, data show.

Healio Gastroenterology and Hepatology presents the following report on highlights from The Liver Meeting Digital Experience.

Axcella Therapeutics announced that it is recruiting for a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AXA1125 in patients with exertional fatigue related to long COVID.

Cotadutide was safe and effective in improving markers of disease activity and fibrosis among patients with biopsy-proven noncirrhotic nonalcoholic steatohepatitis, according to research presented at The Liver Meeting Digital Experience.

Pegbelfermin was safe and effective in improving markers of steatosis, fibrosis and inflammation among patients with nonalcoholic steatohepatitis with stage 3 fibrosis, according to a presentation at The Liver Meeting Digital Experience.

Increased awareness is needed to mitigate burden fatty liver disease and modifiable risk factors among adolescents and young adults, according to research presented at The Liver Meeting Digital Experience.

Improvements in intrahepatic and circulatory inflammation markers were observed after fecal microbiota transplantation in patients with severe alcohol associated hepatitis, according to a presenter at The Liver Meeting Digital Experience.

To streamline and validate diagnosis of and clinical trials in non-alcoholic steatohepatitis, one group is on a mission to determine the best non-invasive tests for all physicians to use, according to a presentation.

Vonafexor induced a strong reduction in liver fat content and improvements in biochemical and imaging markers of liver inflammation and kidney function, according to a presenter at The Liver Meeting Digital Experience.

A 6-month Lactobacillus rhamnosus GG treatment for moderate alcohol-associated hepatitis correlated with a decrease in heavy drinking levels to the social drinking or abstinence levels, according to a presentation.